Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: Results and toxicity

被引:144
作者
Ernst-Stecken, Antje [1 ]
Ganslandt, Oliver
Lambrecht, Ulrike
Sauer, Rolf
Grabenbauer, Gerhard
机构
[1] Univ Erlangen Nurnberg, Dept Radiat Sci, D-8520 Erlangen, Germany
[2] Univ Erlangen Nurnberg, Novalis Shaped Beam Surg Ctr, D-8520 Erlangen, Germany
[3] Univ Erlangen Nurnberg, Dept Radiat Therapy, D-8520 Erlangen, Germany
[4] Univ Erlangen Nurnberg, Dept Neurosurg, D-8520 Erlangen, Germany
关键词
stereotactic radiotherapy; brain metastases; hypofractionated therapy; Novalis (TM) system;
D O I
10.1016/j.radonc.2006.08.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To prospectively evaluate efficacy and side effects of hypofractionated stereotactic radiotherapy (hfSRT) for irresectable brain metastases not amenable to radiosurgery (SRS). Methods and materials: From 1/2003 to 2/2005, 51 patients with 72 brain metastases were included in a prospective phase II-trial and accepted for treatment at the dedicated stereotactic radiosurgery system Novalis (TM) (BrainLAB, Heimstetten, Germany). In case of planned or prior whole brain radiotherapy (WBRT), hfSRT was to be performed with 5 x 6 Gy, otherwise with 5 x 7 Gy. This dose was prescribed to the 90% isodose line which should cover 100% of the planning target volume (PTV). Results: Rates of complete remission (CR), partial remission (PR), no change (NC) and progressive disease (PD) were 66.7%, 18.1%, 12.5% and 2.8%, respectively, after a median follow-up of 7 months. Median survival was 11 months. Disease-specific survival and survival related to brain metastases were strongly associated with the size of gross tumor volume (GTV), the planning target volume (PTV), Karnofsky Performance Score (KPS) and number of metastases. Side effects, i.e., increase in T2w-signal area, duration of steroid intake and size of new or progressive necrotic centre of metastasis, were dependent on the volume of normal brain irradiated with more than 4 Gy per fraction (V-4Gy). Significantly more patients with a V-4Gy >= 23 cc developed radiological signs of side effects from hfSRT. Conclusion: Hypofractionated stereotactic radiotherapy with 5 x 6-7 Gy is an effective and safe treatment for brain metastases not amenable to single high-dose radiosurgery. The normal brain volume receiving > 4 Gy per fraction may not exceed 20 cc. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:18 / 24
页数:7
相关论文
共 54 条
  • [1] Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
    Andrews, DW
    Scott, CB
    Sperduto, PW
    Flanders, AE
    Gaspar, LE
    Schell, MC
    Werner-Wasik, M
    Demas, W
    Ryu, J
    Bahary, JP
    Souhami, L
    Rotman, M
    Mehta, MP
    Curran, WJ
    [J]. LANCET, 2004, 363 (9422) : 1665 - 1672
  • [2] Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull
    Aoyama, HI
    Shirato, H
    Onimaru, R
    Kagei, K
    Ikeda, J
    Ishii, N
    Sawamura, Y
    Miyasaka, K
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (03): : 793 - 800
  • [3] Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
    Aoyama, Hidefumi
    Shirato, Hiroki
    Tago, Masao
    Nakagawa, Keiichi
    Toyoda, Tatsuya
    Hatano, Kazuo
    Kenjyo, Masahiro
    Oya, Natsuo
    Hirota, Saeko
    Shioura, Hiroki
    Kunieda, Etsuo
    Inomata, Taisuke
    Hayakawa, Kazushige
    Katoh, Norio
    Kobashi, Gen
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2483 - 2491
  • [4] ASAI A, 1989, CANCER-AM CANCER SOC, V63, P1962, DOI 10.1002/1097-0142(19890515)63:10<1962::AID-CNCR2820631016>3.0.CO
  • [5] 2-V
  • [6] BEDNARZ G, 1999, NEUROSURGERY, V45
  • [7] Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescence
    Brunner, TB
    Ernst-Stecken, A
    Jeske, I
    Grabenbauer, GG
    Sauer, R
    Distel, L
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 79 (01) : 109 - 114
  • [8] Stereotactic radiosurgery in the treatment of metastatic disease to the brain
    Chen, JCT
    O'Day, S
    Morton, D
    Essner, R
    Cohen-Gadol, A
    MacPherson, D
    Giannotta, SL
    Petrovich, Z
    Yu, C
    Apuzzo, MLJ
    [J]. STEREOTACTIC AND FUNCTIONAL NEUROSURGERY, 1999, 73 (1-4) : 60 - 63
  • [9] Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases
    Chidel, MA
    Suh, JH
    Reddy, CA
    Chao, ST
    Lundbeck, MF
    Barnett, GH
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04): : 993 - 999
  • [10] Combs SE, 2004, STRAHLENTHER ONKOL, V180, P590, DOI 10.1007/s00066-004-1299-x